IGC Pharma, Inc. (IGC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Annual

0 3M 6M 9M FY11: 4.1M FY12: 4.2M FY13: 8M FY14: 2.3M FY15: 7.7M FY16: 6.4M FY17: 580.4K FY18: 2.2M FY19: 5.1M FY20: 4.1M FY21: 898K FY22: 397K FY23: 911K FY24: 1.3M FY25: 1.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 250K 500K 750K FY17: 218.2K FY18: 82K FY19: 132K FY20: 115K FY21: 113K FY22: 194K FY23: 442K FY24: 733K FY25: 619K FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-18M -12M -6M 0 6M 12M 18M FY11: -15.9M FY12: -7.5M FY13: -2.5M FY14: -2.5M FY15: -4.3M FY16: -2.9M FY17: -2.1M FY18: -1.8M FY19: -4.6M FY20: -6.9M FY21: -8.7M FY22: -15.4M FY23: -11.6M FY24: -9.8M FY25: -7.4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-21M -14M -7M 0 7M 14M 21M FY11: -20.2M FY12: -7.8M FY13: -2.3M FY14: -3M FY15: -4.6M FY16: -2.8M FY17: -1.9M FY18: -1.8M FY19: -4.1M FY20: -7.3M FY21: -8.8M FY22: -15M FY23: -11.5M FY24: -13M FY25: -7.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 2.5M 5M 7.5M FY11: 3.9M FY12: 4.8M FY13: 6.5M FY14: 1.9M FY15: 7.1M FY16: 5.5M FY17: 362.1K FY18: 2.1M FY19: 5M FY20: 4M FY21: 785K FY22: 203K FY23: 469K FY24: 612K FY25: 652K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-12M -8M -4M 0 4M 8M 12M FY11: -2.6M FY12: -5M FY13: 564.8K FY14: -1.7M FY15: -2.6M FY16: -157.7K FY17: -1.4M FY18: -1.9M FY19: -3.3M FY20: -8.7M FY21: -10.8M FY22: -7.5M FY23: -7M FY24: -5.2M FY25: -4.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-15M -10M -5M 0 5M 10M 15M FY11: -2.9M FY12: -5M FY13: 238.8K FY14: -1.8M FY15: -2.7M FY16: -279.9K FY17: -1.5M FY18: -2.1M FY19: -3.3M FY20: -13.1M FY21: -12.3M FY22: -7.7M FY23: -7.4M FY24: -5.3M FY25: -4.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY11: 15.1M FY12: 2.9M FY13: 7M FY14: 8.2M FY15: 14.8M FY16: 16.4M FY17: 25.7M FY18: 27.9M FY19: 35.4M FY20: 39.5M FY21: 42M FY22: 50M FY23: 52.6M FY24: 58.8M FY25: 76.5M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q4 '12: -2.66 Q1 '13: -2.76 Q2 '13: -2.74 Q3 '13: -2.60 Q4 '13: -0.37 Q1 '14: -0.32 Q2 '14: -0.39 Q3 '14: -0.48 Q4 '14: -0.39 Q1 '15: -0.42 Q2 '15: -0.40 Q3 '15: -0.41 Q4 '15: -0.33 Q1 '16: -0.24 Q2 '16: -0.21 Q3 '16: -0.18 Q4 '16: -0.17 Q1 '17: -0.16 Q2 '17: -0.14 Q3 '17: -0.12 Q4 '17: -0.07 Q1 '18: -0.07 Q2 '18: -0.06 Q3 '18: -0.08 Q4 '18: -0.07 Q1 '19: -0.07 Q2 '19: -0.09 Q3 '19: -0.10 Q4 '19: -0.14 Q1 '20: -0.15 Q2 '20: -0.15 Q3 '20: -0.16 Q4 '20: -0.18 Q1 '21: -0.20 Q2 '21: -0.21 Q3 '21: -0.23 Q4 '21: -0.22 Q1 '22: -0.21 Q2 '22: -0.26 Q3 '22: -0.25 Q4 '24: -0.22 Q1 '25: -0.21 Q2 '25: -0.18 Q3 '25: -0.11 Q4 '25: -0.09 Q1 '26: -0.08 Q2 '26: -0.08 Q3 '26: -0.07 Q4 '26: -0.07 Q1 '27: -0.08 Q4 '12 Q3 '14 Q2 '16 Q1 '18 Q4 '19 Q3 '21 Q2 '25 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.